Clinical Trial Update: Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating antigen peptide-specific DC-CTL cells with decitabine for malignant tumors is in early testing with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Tumor

Drugs mentioned

• Decitabine (Decitabine)
• antigen peptide-specific DC-CTL cells

Snippet

Sponsor: Shenzhen University General Hospital | Conditions: Malignant Tumor | Phase 1, Phase 2 | Status: UNKNOWN